Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Report Available: Viral Conjunctivitis - Pipeline Review, H2 2013


Print article Print article
2013-12-22 01:47:50 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Viral Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Viral Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis. Viral Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated

disease.

Full Report Details at
- www.fastmr.com/prod/755154_viral_conjunctivitis_pipeline_review_ ..

Scope

* A snapshot of the global therapeutic scenario for Viral Conjunctivitis.
* A review of the Viral Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Viral Conjunctivitis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: NanoViricides, Inc., NovaBay Pharmaceuticals, Inc., Starpharma Holdings Limited, Foresight Biotherapeutics, Inc., Redox Pharmaceutical Corporation

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Viral Conjunctivitis Overview
Therapeutics Development
An Overview of Pipeline Products for Viral Conjunctivitis
Viral Conjunctivitis Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Viral Conjunctivitis Therapeutics - Products under Development by Companies
Companies Involved in Viral Conjunctivitis Therapeutics Development
NanoViricides, Inc.
NovaBay Pharmaceuticals, Inc.
Starpharma Holdings Limited
Foresight Biotherapeutics, Inc.
Redox Pharmaceutical Corporation
Viral Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
auriclosene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTC-96 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rebamipide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EKC-Cide-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FST-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-727 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-638 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-704 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APD-209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viral Conjunctivitis Therapeutics - Drug Profile Updates
Viral Conjunctivitis Therapeutics - Dormant Products
Viral Conjunctivitis - Product Development Milestones
Featured News & Press Releases
May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
Apr 08, 2013: NovaBay Pharma Enrolls First Patients In Brazil In BAYnovation Phase IIb Study For Adenoviral Conjunctivitis
Jan 03, 2013: NovaBay Pharma Expands Global Ophthalmology Study Of Pink Eye To India
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
May 31, 2012: NovaBay Pharma Obtains Seven New Patents For Aganocide Compounds
May 17, 2012: NovaBay Enrolls First Patient In BAYnovation Phase IIb Study For Adenoviral Conjunctivitis
Jan 23, 2012: NovaBay Prepares To Launch Global Phase IIb Ophthalmic Study Of NVC-422
Nov 14, 2011: NovaBay's Aganocide Compound, NVC-422, Featured In Drugs Of The Future
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
May 18, 2011: NovaBay Reports Results From Phase II Clinical Trial Of NVC-422 For Adenoviral Conjunctivitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755154&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com